Pulmonary Arterial Hypertension and Associated Cardiovascular Disease Detection Using Artificial Intelligence

Not yet recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

August 1, 2027

Conditions
Pulmonary HypertensionCardiovascular Diseases (CVD)
Interventions
DEVICE

AI Stethoscope

"Patients attending routine echocardiography who satisfy the inclusion and exclusion criteria will be approached before their echocardiography appointment to obtain informed consent to participate in the study. On providing informed consent, each patient will receive a non-invasive, external examination with a smart stethoscope that records a 3-lead electrocardiogram (ECG) and phonocardiogram (PCG) waveforms. This examination will require only one study visit (during routine echocardiography) and no additional visits. The stethoscope is a fully CE-marked device.~In addition to echocardiography parameters and smart stethoscope waveforms, baseline demographics, clinical and medication history will be recorded. These data points will be re-examined at 24 months following enrolment (via chart review)."

Trial Locations (1)

Unknown

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
collaborator

Imperial College Healthcare NHS Trust

OTHER

lead

Imperial College London

OTHER